

# Lei Guo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2445630/publications.pdf>

Version: 2024-02-01

10  
papers

249  
citations

1163117

8  
h-index

1372567

10  
g-index

11  
all docs

11  
docs citations

11  
times ranked

301  
citing authors

#	ARTICLE	IF	CITATIONS
1	The long non-coding RNA DANCR regulates the inflammatory phenotype of breast cancer cells and promotes breast cancer progression <i>via</i> EZH2-dependent suppression of SOCS3 transcription. <i>Molecular Oncology</i> , 2020, 14, 309-328.	4.6	60
2	Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 811.	2.8	37
3	Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data. <i>Clinical Cancer Research</i> , 2021, 27, 4634-4641.	7.0	32
4	LncRNA GNAS-AS1 facilitates ER+ breast cancer cells progression by promoting M2 macrophage polarization via regulating miR-433-3p/GATA3 axis. <i>Bioscience Reports</i> , 2020, 40, .	2.4	32
5	Novel roles of <i>Vmp1</i> : Inhibition metastasis and proliferation of hepatocellular carcinoma. <i>Cancer Science</i> , 2012, 103, 2110-2119.	3.9	21
6	<i>Polyporus umbellatus</i> inhibited tumor cell proliferation and promoted tumor cell apoptosis by down-regulating AKT in breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 2016, 83, 526-535.	5.6	19
7	miR-574-5p attenuates proliferation, migration and EMT in triple-negative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKI/TAZ/CTGF axis. <i>International Journal of Oncology</i> , 2020, 56, 1240-1251.	3.3	19
8	The transition of alcohol control in China 1990-2019: Impacts and recommendations. <i>International Journal of Drug Policy</i> , 2022, 105, 103698.	3.3	9
9	YAP1/MMP7/CXCL16 axis affects efficacy of neoadjuvant chemotherapy via tumor environment immunosuppression in triple-negative breast cancer. <i>Gland Surgery</i> , 2021, 10, 2799-2814.	1.1	3
10	The prognostic effect of HER2 heterogeneity and YAP1 expression in HER2 positive breast cancer patients: a retrospective study. <i>Gland Surgery</i> , 2022, 11, 451-465.	1.1	0